CYP19A1 and breast carcinoma: In addition, it is worth mentioning that we reported the second case of PESCC with a history of breast cancer who had been taking the aromatase inhibitor drug “exemestane” for a long time to reduce the estrogen level, indicating a low estrogen level may be also a risk factor for the pathogenesis of PESCC.